Offering is comprised of 12% convertible debentures due June 7, 2014
By Devika Patel
Knoxville, Tenn., June 13 - Amarantus Bioscience Holdings, Inc. completed a $250,000 private placement of 12% convertible debentures due June 7, 2014 on June 7, according to an 8-K filed Thursday with the Securities and Exchange Commission.
The notes are convertible into common shares at $0.032 per share. The company may repurchase the debentures at 125. The conversion price reflects a 6.67% premium to the June 6 closing share price of $0.03.
Aegis Capital was the agent.
The biotechnology company is based in Sunnyvale, Calif.
| Issuer: | Amarantus Bioscience Holdings, Inc.
|
| Issue: | Convertible debentures
|
| Amount: | $250,000
|
| Maturity: | June 7, 2014
|
| Coupon: | 12%
|
| Conversion price: | $0.032
|
| Call: | At 125
|
| Warrants: | No
|
| Agent: | Aegis Capital
|
| Settlement date: | June 7
|
| Stock symbol: | OTCBB: AMBS
|
| Stock price: | $0.03 at close June 6
|
| Market capitalization: | $16.36 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
